Wednesday June 26, 6:30 am Eastern Time
Press Release
SOURCE: Isotechnika Inc.
Isotechnika and Roche Announce Completion of Patient Recruitment for ISA(TX)247 Phase II Clinical Trial in Psoriasis
EDMONTON, June 26 /CNW/ - Dr. Randall Yatscoff, President and COO of Isotechnika Inc. announced today that the Company has achieved its objective of enrolling 200 patients in the Phase II human clinical trial evaluating its lead drug ISA(TX)247 as a potential treatment therapy for moderate to severe psoriasis. ISA(TX)247 is being developed under a global collaboration agreement with Roche.
The trial, which is being performed at twelve centers in Canada, is a double blinded study. It is randomized with 80 patients receiving the high dose (1.5 mg/ kg/d bid ISA(TX)247), 80 patients receiving the low dose (0.5 mg/kg/d bid ISA(TX)247) and 40 patients on placebo. It is expected that the last patient will complete the 90 day study, this fall.
"We are pleased with having achieved complete recruitment for this trial within our expected timelines. Subsequent to the completion of the trial, the data will be compiled and analyzed." said Dr. Yatscoff.
About Isotechnika Inc.
Isotechnika Inc. and Roche recently signed an agreement for the global co-development and commercialization of Isotechnika's innovative transplant drug, ISA(TX)247. This agreement represents the largest Canadian drug development deal between a large pharma and a biotech company. Isotechnika Inc. is an international life sciences company headquartered in Edmonton, Alberta with additional operations in Arizona. The company is focused on the development of immunosuppressive therapeutic drugs for use in organ transplant patients and in the treatment of autoimmune diseases. Its founders and scientific team have developed a novel, multi-platform drug, ISA(TX)247, which has progressed through discovery, pre-clinical and Phase 1 human clinical trials in less than five years. ISA(TX)247 is currently undergoing Phase 2 human clinical trials in renal transplantation and psoriasis and has the potential to become the market leader in immunosuppressant therapy; an established market for drugs of this class is in excess of 2.2 billion USD per year globally. Isotechnika Inc. is a S&P/TSX Composite Index company publicly traded under the symbol ISA. More information on Isotechnika can be found at www.isotechnika.com.
For further information
Gordon Agopsowicz, Director, Investor Relations, Isotechnika Inc., (780) 487-1600 Ext. 245, (780) 484-4105 (fax), gagopsowicz@isotechnika.com |
